GlassScriptPhysician profile
Craig R Hildreth
NPI 1851393136
$10,818.76
in general payments reported to CMS, 2019-2025
41 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,730 · 2020: $1,894 · 2021: $1,040 · 2022: $1,394 · 2023: $165 · 2024: $235 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.81 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $6,958.95 | 2019-2022 | |
| Genentech USA, INC. | $310.73 | 2019-2020 | |
| Amgen INC. | $227.08 | 2019-2020 | |
| Celgene Corporation | $218.32 | 2019 | |
| Abbvie INC. | $216.99 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $214.69 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $171.76 | 2019-2025 | Imfinzi |
| Gilead Sciences, INC. | $169.19 | 2019-2024 | |
| Myriad Genetic Laboratories, INC. | $167.76 | 2021-2023 | Myrisk |
| Janssen Biotech, INC. | $164.37 | 2019 | |
| Pfizer INC. | $162.99 | 2019-2020 | |
| Lilly USA, LLC | $150.16 | 2019-2020 | |
| Beone Medicines USA, INC. | $148.02 | 2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.63 | 2019-2024 | Gilotrif |
| Incyte Corporation | $128.41 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Hildreth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.